Epstein-barr virus vaccination of transplant candidates: Light at the end of the tunnel?

Transplantation

Volumn 88, Issue 8, 2009, Pages 976-977

  Allen, Upton D ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EPSTEIN BARR VIRUS VACCINE; GLYCOPROTEIN 350 EPSTEIN BARR VIRUS VACCINE; RECOMBINANT GLYCOPROTEIN 350 VACCINE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ADAPTIVE IMMUNITY; B LYMPHOCYTE; BURKITT LYMPHOMA; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DESIGN; DRUG EFFICACY; EPSTEIN BARR VIRUS; GRAFT RECIPIENT; HODGKIN DISEASE; HOST; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; IMMUNOGENICITY; IMMUNOLOGY; INFECTIOUS MONONUCLEOSIS; INNATE IMMUNITY; LYMPHOPROLIFERATIVE DISEASE; NASOPHARYNX CARCINOMA; NONHUMAN; NOTE; ORGAN TRANSPLANTATION; POSTTRANSPLANTATION LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; RISK; SYMPTOM; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VACCINATION;

CHILD, PRESCHOOL; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; MEMBRANE GLYCOPROTEINS; POSTOPERATIVE COMPLICATIONS; PROTEIN SUBUNITS; TRANSPLANTATION IMMUNOLOGY; VIRAL MATRIX PROTEINS; VIRAL VACCINES;

EID: 70350444561     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181b99876     Document Type: Note

References (7)

1. Rees L, Tizard EJ, Morgan AJ, et al. A phase I trial of Epstein-Barr virus gp350 vaccine for children with chronic kidney disease awaiting transplantation. Transplantation 2009, 88: 1025.
2. Moss DJ, Burrows SR, Khanna R. Developing vaccines against EBV-associated diseases. In: Roberston ES, ed. Epstein-Barr virus. Norfolk, VA, Caister Academic Press 2005, p 652.
3. Morgan AJ, Wilson AD. The development of Epstein-Barr virus vaccines. In: Tselis A, Jenson HB, eds. Informa health care. New York, Taylor Francis Group 2006, p 375.
4. Gu SY, Huang TM, Ruan L, et al. First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen. Dev Biol Stand 1995; 84: 171.
5. Sokal EM, Hoppenbrouwers K, Vandermeulen C, et al. Recombinant gp350 vaccine for infectious mononucleosis: A phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immuno-genicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J Infect Dis 2007; 196: 1749.
6. Gottschalk S, Heslop HE, Roon CM. Treatment of Epstein-Barr virus-associated malignancies with specific T cells. Adv Cancer Res 2002; 84: 175.
7. Savoldo B, Goss JA, Hammer MM, et al. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cyto-toxic T lymphocytes (CTLs). Blood 2006; 108: 2942.